explore -WSS

explore

author：knowledge 2025-10-01 15:39:39 - browse：5

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： FDA clears Verve to begin U.S. study of gene

explore

WSS

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Reconstructing family trees of blood cells may help predict disease

CZI to create biohub to build anti

Pancreatic cancer early detection could be helped by AI

Bernie Sanders is gearing up to subpoena pharma CEOs

Vertex non

focus

explore

leisure time

Supreme Court strikes down use of affirmative action

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: The economic case for universal basic health care

Activists slam private health insurers over coverage restrictions

Zyn nicotine pouches become unlikely player in latest culture war

Medical records are filled with copy

How generative AI ratchets up security threats for health systems

How to save PrEP access — and even expand it

Boston competes with Raleigh

explore

The Affordable Care Act has saved billions in health care costs

Why a market frenzy over new weight loss drugs defies logic

Why a market frenzy over new weight loss drugs defies logic

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Reconstructing family trees of blood cells may help predict disease

FDA clears Verve to begin U.S. study of gene

focus

explore

hotspot

leisure time